Cancer Research UK questions whether the National Cancer Plan will deliver on clinical trials

Cancer Research UK has published a policy and insight commentary asking whether the National Cancer Plan — the UK government's framework for improving cancer outcomes — will deliver on its stated ambition of boosting clinical trial participation. The piece, published on 4 August 2026, focuses on the structural and systemic barriers that have historically constrained the UK's clinical trial infrastructure, including site activation timelines, patient recruitment, and workforce capacity.

Whilst the National Cancer Plan sets out intent to expand access to trials, Cancer Research UK's commentary appears to interrogate the mechanisms by which this would be achieved, and whether sufficient resource and accountability structures are in place. Clinical trials are central to the development of new cancer treatments, including genomics-informed and targeted therapies that are increasingly relevant to oncology practice and hereditary cancer research.

The full commentary is available on the Cancer Research UK news site. Readers in oncology, health policy, and cancer genetics research are likely to find the analysis relevant, particularly given ongoing discussions about the UK's competitiveness as a location for genomically stratified cancer trials.